Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma

Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR). Nimotuzumab has been granted approval for use in squamous cell carcinoma of head and neck (SCCHN), glioma and nasopharyngeal cancer in different countries. This is a multi-center, randomized controlled trial, with the purpose to evaluate the therapeutic efficacy and safety of nimotuzumab combined with induction chemotherapy plus chemoradiation and adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma.

Trial Details

NCT ID
NCT05717790
Phase
NA
Sponsor
Fourth Affiliated Hospital of Guangxi Medical University
Status
RECRUITING
Cancer Type
Nasopharyngeal Head and Neck Cancer
Interventions
  • Nimotuzumab
  • Gemcitabine
  • Cisplatin
  • Intensity-modulated radiotherapy
Locations (sample)
  • Baise City, Guangxi, China|23.89013,106.62684
  • Baise City, Guangxi, China|23.89013,106.62684
  • Guilin, Guangxi, China|25.28022,110.29639
  • Guilin, Guangxi, China|25.28022,110.29639
  • Liuzhou, Guangxi, China|24.32405,109.40698

Key Eligibility Criteria

  • Age: 18 to 70.
  • Pathological type: non-keratinizing carcinoma (World Health Organization criteria).
  • Diagnosed with LANPC (stage III-IV, except for patients with T3N0)) according to the 8th edition clinical staging system of the American Joint Comm…
  • ECOG performance score: 0 to 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Nasopharyngeal Head and Neck Cancer Trials on Trialify →